


Amendments to the Claims:

1. (Currently Amended) A compound of formula (I)



(I)

or a salt, or solvate thereof, ~~or physiologically functional derivative thereof~~,
wherein:

n is an integer of from 2 to 8;

m is an integer of from 3 to 11, with the proviso that the sum of n + m is from 5 to 19;

R¹ is hydrogen or -XSO₂NR⁶R⁷;

wherein X is -(CH₂)_p - or C₂₋₆ alkenylene;

p is an integer from 0 to 6;

R⁶ and R⁷ are independently selected from hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, CONR⁸R⁹, phenyl and phenyl(C₁₋₄alkyl)-,

or R⁶ and R⁷, together with the nitrogen atom to which they are bonded, form a 5-, 6- or 7- membered nitrogen – containing ring;

and R^6 and R^7 are each independently optionally substituted by 1 or 2 groups independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy-substituted C_{1-6} alkoxy, C_{1-6} haloalkyl, CO_2R^8 , $SO_2R^8R^9$, $-CONR^8R^9$, $-NR^8C(O)R^9$ or a 5-, 6- or 7-membered heterocyclic ring;


R^8 and R^9 are independently selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, phenyl and phenyl(C_{1-6} alkyl)-;

R^2 and R^3 are independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halo, phenyl and C_{1-6} haloalkyl;


R^4 and R^5 are independently selected from hydrogen and C_{1-4} alkyl with the proviso that the total number of carbon atoms in R^4 and R^5 is not more than 4,

and


Ar is a group selected from the group consisting of:



(a)




(b)



(c)

and



(d)

wherein R^{11} represents hydrogen, halogen, $-(CH_2)_4OR^{14}$, $-NR^{14}C(O)R^{15}$, $-NR^{14}SO_2R^{15}$, $-SO_2NR^{14}R^{15}$, $-NR^{14}R^{15}$, $-OC(O)R^{16}$ or $OC(O)NR^{14}R^{15}$, and R^{10} represents hydrogen, halogen or C_{1-4} alkyl;

or R^{11} represents $-NHR^{17}$ and R^{10} and $-NHR^{17}$ together form a 5- or 6-membered heterocyclic ring;

R^{12} represents hydrogen, halogen, $-OR^{14}$ or $-NR^{14}R^{15}$; $-OC(O)R^{16}$ or $-OC(O)NR^{14}R^{15}$;

R^{13} represents hydrogen, halogen, halo C_{1-4} alkyl, $-OR^{14}$ or $-NR^{14}R^{15}$;

R^{14} and R^{15} each independently represents hydrogen or C_{1-4} alkyl, or in the groups

$-NR^{14}R^{15}$, $-SO_2NR^{14}R^{15}$ and $-OC(O)NR^{14}R^{15}$, R^{14} and R^{15} independently represent hydrogen or C_{1-4} alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring,

R^{16} represents an aryl (eg phenyl or naphthyl) group which may be unsubstituted or substituted by one or more substituents selected from halogen, C_{1-4} alkyl, hydroxy, C_{1-4} alkoxy or halo C_{1-4} alkyl; and

q is zero or an integer from 1 to 4;

provided that when R^1 is hydrogen

Ar is not a group (a) wherein;

R^{11} is $-(CH_2)_qOR^{14}$, q is zero or 1 and R^{12} is OR^{14} ,

or R^{11} is $-(CH_2)_qOR^{14}$, q is zero and R^{13} is OR^{14} ,

or R^{11} is $-NR^{14}SO_2R^{15}$ or $NR^{14}COR^{15}$ and R^{12} is OR^{14} ,

or R^{11} and R^{13} both represent halogen and R^{12} is $NR^{14}R^{15}$;

Ar is not a group (b) wherein R^{11} is $-(CH_2)_qOR^{14}$ and R^{12} is OR^{14} ;

Ar is not a group (c),

and when R^1 is $XSO_2NR^6R^7$, Ar is not a group (a) wherein

R^{11} is $(CH_2)_qOR^{14}$ or $NR^{14}COR^{15}$, and R^{12} is OR^{14} .

2. (Currently Amended) A compound of formula (I) according to claim 1 wherein, in the group Ar, R^{11} represents halogen, $-(CH_2)_qOR^{14}$, $-NR^{14}C(O)R^{15}$, $-NR^{14}SO_2R^{15}$, $-SO_2NR^{14}R^{15}$, $-NR^{14}R^{15}$, $-OC(O)R^{16}$ or $OC(O)NR^{14}R^{15}$,

and R^{10} represents hydrogen,

or R¹¹ represents –NHR¹⁷ and R¹⁰ and –NHR¹⁷ together form a 5- or 6-membered heterocyclic ring;

and

R¹³ represents hydrogen, halogen, halo, C₁₋₄ alkyl, –OR¹⁴, or –NR¹⁴R¹⁵;

~~and all other substituents are as defined in claim 1.~~

3. (Currently Amended) A compound of formula (I) according to claim 1 ~~or claim 2~~ wherein the group R¹ is attached to the meta-position relative to the –O-(CH₂)_m link.


4. (Currently Amended) A compound of formula (I) according to claim 1 ~~any of claims 1 to 3~~ wherein R¹ represents SO₂NR⁶R⁷ wherein R⁶ and R⁷ are independently selected from hydrogen and C₁₋₆alkyl.

5. (Currently Amended) A compound of formula (I) according to claim 1 ~~any of claims 1 to 4~~ wherein R⁴ and R⁵ are independently selected from hydrogen and methyl.


6. (Currently Amended) A compound of formula (I) according to claim 1 ~~any of claims 1 to 5~~ wherein R² and R³ each represent hydrogen.

7. (Currently Amended) A compound of formula (I) according to claim 1 ~~any of claims 1 to 6~~ wherein n is 5 or 6 and m is 3 or 4 such that m + n is 8, 9 or 10.


8. (Currently Amended) A compound of formula (I) according to claim 1 ~~any of claims 1 to 7~~ wherein Ar represents a group selected from the group consisting of:




(i)




(ii)




(iii)




(iv)




(v)




(vi)




(vii)




(viii)




(ix)




(x)




(xi)




(xii)




(xiii)




(xiv)




(xv)




(xvi)




(xvii)



(xviii)



(xix)



(xx)

9. (Currently Amended) A compound of formula (I) according to claim 8 ~~any of claims 1 to 8~~ wherein R^1 is hydrogen and Ar is selected from a the group consisting of structure (ii), (v), (vi), (viii), (ix), (xi), (xii), (xiii), (xiv), (xv), (xvi), (xvii) and (xviii).

10. (Currently Amended) A compound of formula (I) according to claim 8 ~~any of claims 1 to 8~~ wherein R^1 is $XSO_2NR^6R^7$ and Ar is selected from a the group consisting of structure (iii), (iv), (xiv), (xv), (xvi) and (xix).

11. (Currently Amended) A compound ~~of formula (I)~~ selected from the group consisting of:

8-Hydroxy-5-((1*R*)-1-hydroxy-2-[[6-(4-phenylbutoxy)hexyl]amino]ethyl)quinolin-2(1*H*)-one;

3-{4-[(6-[(2*R*)-2-Hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino)hexyl]oxy}butyl}benzenesulfonamide;
5-Hydroxy-8-(1-hydroxy-2-[(6-(4-phenylbutoxy)hexyl)amino]ethyl)-2*H*-1,4-benzoxazin-3(4*H*)-one;
3-{4-[(6-[(2-hydroxy-2-(5-hydroxy-3-oxo-3,4-dihydro-2*H*-1,4-benzoxazin-8-yl)ethyl]amino)hexyl]oxy}butyl}benzenesulfonamide;
4-Hydroxy-7-((1*R*)-1-hydroxy-2-[(6-(4-phenylbutoxy)hexyl)amino]ethyl)-1,3-benzothiazol-2(3*H*)-one;
4-Hydroxy-7-(1-hydroxy-2-[(6-(4-phenylbutoxy)hexyl)amino]ethyl)-1,3-benzothiazol-2(3*H*)-one;
3-{4-[(6-[(2*R*)-2-(3-Fluoro-4-hydroxyphenyl)-2-hydroxyethyl]amino)hexyl]oxy}butyl}benzenesulfonamide;
3-(4-[(6-[(2-Hydroxy-2-[5-hydroxy-6-(hydroxymethyl)pyridin-2-yl]ethyl]amino)hexyl]oxy}butyl)benzenesulfonamide;
3-[4-[(6-[(2*R*)-2-Hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)amino]hexyl]oxy}butyl]benzenesulfonamide;
3-{3-[(7-[(2*R*)-2-(3-Fluoro-4-hydroxyphenyl)-2-hydroxyethyl]amino)heptyl]oxy}propyl}benzenesulfonamide;
3-(3-[(7-[(2-Hydroxy-2-[5-hydroxy-6-(hydroxymethyl)pyridin-2-yl]ethyl]amino)heptyl]oxy}propyl)benzenesulfonamide;
3-[3-[(7-[(2*R*)-2-Hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)amino]heptyl]oxy}propyl]benzenesulfonamide;
3-{3-[(7-[(2*R*)-2-Hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino)heptyl]oxy}propyl}benzenesulfonamide;
3-(3-[(7-[(2*R*)-2-[3-(Formylamino)-4-hydroxyphenyl]-2-hydroxyethyl]amino)heptyl]oxy}propyl)benzenesulfonamide;

a salt thereof , and a solvate thereof, or physiologically functional derivative thereof.

12. (Currently Amended) A method for the prophylaxis or treatment of a clinical condition in a mammal, ~~such as a human~~, for which a selective β_2 -adrenoreceptor agonist is indicated, which comprises administering ~~administration of~~ a therapeutically effective amount of a compound of formula (I) according to claim 1 ~~any of claims 1 to 11~~, or a pharmaceutically acceptable salt, or solvate thereof, ~~or physiologically functional derivative thereof~~.


13. (Canceled)

14. (Currently Amended) A pharmaceutical formulation comprising a compound of formula (I), according to claim 1 ~~any of claims 1 to 11~~, or a pharmaceutically acceptable salt, or solvate thereof, ~~or physiologically functional derivative thereof~~, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

15. (Canceled)


16. (Currently Amended) A process for the preparation of a compound of formula (I), according to claim 1 ~~any of claims 1 to 11~~, or a salt, or solvate thereof, ~~or physiologically functional derivative thereof~~, which comprises:

(a) deprotecting ~~deprotection of~~ a protected intermediate of formula (II):




or a salt or solvate thereof, wherein R^1 , R^2 , R^3 , R^4 , R^5 , m and n are as defined for the compounds of formula (I) R^{25} represents an optionally protected form of Ar, and R^{26} and R^{27} each independently represent either hydrogen or a protecting group, provided that the compound of formula (II) contains at least one protecting group;

~~(b) — reacting a compound of formula (XIII):~~




~~Wherein Ar is as defined above with a compound of formula (VI):~~




(VI)

Wherein L is a leaving group such as halo (typically chloro, bromo or iodo) or a sulphonate (typically methanesulphonate) and $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, n$ and m are as defined for compounds of formula (I).

(c) reacting a compound of formula (XV):




wherein L is a leaving group as hereinbefore defined, with an amine of formula (XVI):




(XVI)

wherein $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, n$ and m are as defined for formula (I); and


(d) (i) reacting a compound of formula (XIII):




Wherein Ar is as hereinbefore defined and R^{34} is a chiral auxiliary group,
 with a compound of formula (XVII):



wherein $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4, n$ and m are as hereinbefore defined;
 followed where necessary by removal of said chiral auxiliary group R^{34} ;
 or (ii) reacting a compound of formula (XVIII):



wherein Ar is as hereinbefore defined; with an amine of formula (XVI):



~~as hereinbefore defined,~~

~~under conditions suitable to effect reductive amination,~~

wherein said process may further optionally comprise one or more of ~~followed~~
~~by~~ the following steps in any order:

- ~~(i) optional removal of~~ removing any protecting groups;
- ~~(ii) optional separation of~~ separating an enantiomer from a mixture of enantiomers;
- ~~(iii) optional conversion of~~ converting the product to a corresponding salt, solvate, or
- ~~(iv) optional conversion of~~ converting a group R^1 , R^2 and/or R^3 to another group R^1 , R^2 and/or R^3 , ~~or physiologically functional derivative thereof.~~

17. (New) A compound of the formula (I) according to claim 1, wherein m is an integer ranging from 3 to 7.

18. (New) A compound of the formula (I) according to claim 1, wherein the sum of $n + m$ ranges from 5 to 12.

19. (New) A compound of the formula (I) according to claim 1, wherein p is an integer ranging from 0 to 4.


20. (New) A method according to claim 12, wherein the mammal is a human.

21. (New) A method according to claim 12, wherein the clinical condition is asthma.


22. (New) A method according to claim 12, wherein the clinical condition is COPD.

23. (New) A process for the preparation of a compound of formula (I), according to claim 1 or a salt, or solvate thereof, which comprises:

reacting a compound of formula (XIII):



Wherein Ar is as defined above with a compound of formula (VI):



(VI)

wherein L is a leaving group and R¹, R², R³, R⁴, R⁵, n and m are as defined for compounds of formula (I);

wherein said process may further optionally comprise one or more of following steps in any order:

- (i) removing any protecting groups;
- (ii) separating an enantiomer from a mixture of enantiomers;
- (iii) converting the product to a corresponding salt, solvate, or
- (iv) converting a group R¹, R² and/or R³ to another group R¹, R² and/or R³.

24. (New) A process according to claim 23, wherein the leaving group comprises a halo group.

25. (New) A process according to claim 24, wherein the halo group is selected from the group consisting of chloro, bromo, and iodo.

26. (New) A process according to claim 23, wherein the leaving group comprises a sulphonate group.


27. (New) A process according to claim 26, wherein the sulphonate group is a methanesulphonate group.

28. (New) A process for the preparation of a compound of formula (I), according to claim 1, or a salt or solvate thereof, which comprises:

reacting a compound of formula (XV):



wherein L is a leaving group, with an amine of formula (XVI):



wherein R^1 , R^2 , R^3 , R^4 , R^5 , n and m are as defined for formula (I); and
wherein said process may further optionally comprise one or more of the following steps in any order:

- (i) removing any protecting groups;
- (ii) separating an enantiomer from a mixture of enantiomers;
- (iii) converting the product to a corresponding salt, solvate, or
- (iv) converting a group R^1 , R^2 and/or R^3 to another group R^1 , R^2 and/or R^3 .

29. (New) A process according to claim 28, wherein the leaving group comprises a halo group.


30. (New) A process according to claim 28, wherein the halo group is selected from the group consisting of chloro, bromo, and iodo.

31. (New) A process according to claim 28, wherein the leaving group comprises a sulphonate group.

32. (New) A process according to claim 28, wherein the sulphonate group is a methanesulphonate group.


33. (New) A process for the preparation of a compound of formula (I), according to claim 1 or a salt or solvate thereof, wherein said process is selected from the group consisting of (i) and (ii):

(i) reacting a compound of formula (XIII):




Wherein Ar is as hereinbefore defined and R³⁴ is a chiral auxiliary group,

with a compound of formula (XVII):




wherein R^1 , R^2 , R^3 , R^4 , n and m are as hereinbefore defined;
 optionally followed by removing said chiral auxiliary group R^{34} ;

and (ii) reacting a compound of formula (XVIII):



wherein Ar is as hereinbefore defined; with an amine of formula (XVI):



as hereinbefore defined,

under conditions suitable to effect reductive amination,

wherein said process may further optionally comprise one or more of the following steps in any order:

- (i) removing any protecting groups;
- (ii) separating an enantiomer from a mixture of enantiomers;
- (iii) converting the product to a corresponding salt, solvate,
- (iv) converting a group R^1 , R^2 and/or R^3 to another group R^1 , R^2 and/or R^3 .